Market News

Genocea Up 5% On FDA Nod For Cancer Therapy Application; Street Sees 353% Upside

Genocea Biosciences announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its GEN-011 cancer immunotherapy, sending shares up 5% in Tuesday’s pre-market session.

Genocea (GNCA), which is developing next-generation neoantigen immunotherapies in multiple tumor types, said that following the IND acceptance, it will initiate a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy. The trial will evaluate safety, T cell proliferation and persistence as well as clinical activity.

GEN-011 is an adoptive T cell therapy targeting neoantigens and is designed to improve upon the limitations of tumor-infiltrating lymphocytes (TIL) and T-cell receptors (TCR) therapies.

“GEN-011 builds on the power of our ATLAS platform, as demonstrated in our GEN-009 clinical trial, to identify the relevant neoantigens which drive robust anti-tumor T cell responses in patients,” said Genocea CEO Chip Clark. “Using a patient’s peripheral T cells, already programmed to kill cancer cells with relevant neoantigens, enables this non-engineered therapy to rapidly scale. We therefore believe GEN-011 may eventually offer efficacy, accessibility and cost advantages to patients and providers.”

Genocea plans to enroll up to 24 patients across several tumor types in the Phase 1/2 trial. In one cohort, patients will receive multiple low doses of GEN-011 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will receive a single GEN-011 dose after lymphodepletion and a high dose of IL-2.

Shares in Genocea are already up 12% so far this year, with the $10.50 average analyst price target implying a whopping 353% upside potential lies ahead.  

Needham analyst Chad Messer last week maintained a Buy rating on the stock with a $7 price target (202% upside potential).

“We believe GNCA is undervalued versus peer neo-antigen cancer vaccine companies despite Genocea’s early clinical stage,” Messer wrote in a note to investors. “We base our price target on a projected $500M enterprise value, which we view as a modest premium to the median value of comparable companies in the space. To that we add YE:20 estimated cash of $75M and subtract Hercules debt arriving at $561M.”

The rest of the Street shares Messer’s bullish outlook. The Strong Buy analyst consensus boasts 4 unanimous Buy ratings. (See GNCA stock analysis on TipRanks)

Related News:
Teva Launches Two Digital Inhalers For Asthma Patients

Illumina Confirms $8B Acquisition Of Cancer-Detection Firm Grail
AstraZeneca-Merck’s Lynparza Gets Recommended By EU For Prostate, Ovarian Cancers

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More